Marksans Pharma, a prominent player in the pharmaceutical industry, specializes in formulating prescription and over-the-counter drugs across key therapeutic segments including Oncology, Gastroenterology, Antidiabetic, Antibiotics, Cardiovascular, Pain Management, and Gynaecology.
In this article, we will comprehensively explore Marksans Pharma, discussing its history, operational scope, focus areas, achievements, and impactful contributions to healthcare. Join us as we uncover all aspects of Marksans Pharma and its significant presence in the medical field.
About Marksans Pharma
Marksans Pharma’s revenue mix in FY23 reflects a diversified portfolio across various therapeutic segments. The highest revenue contribution came from Pain Management products at 44%, followed by Cough & Cold remedies at 14%, and Cardiovascular System medications at 9%. The company’s focus on Over-the-Counter (OTC) products intensified, with OTC revenue accounting for approximately 74% in FY23, up from 69% in FY22, while Prescription (RX) revenue decreased to around 26% in FY23 from 31% in FY22.
Geographically, the revenue split for H1FY24 shows a significant presence in the US & North America (40%), Europe & UK (45%), and smaller contributions from Australia & Canada (10%) and the Rest of the World (5%).
Marksans Pharma boasts a robust product portfolio comprising over 1500 Stock Keeping Units (SKUs) and more than 300 products, including tablets (plain, enteric-coated, and film-coated), hard & soft gelatin capsules, oral liquids, and ointments. In the USA, the company operates through its wholly-owned subsidiary, Time Cap Labs Inc, acquired in June 2015, catering to major retailers like Target, Walmart, Walgreens, and Kroger with a range of Private Label OTC and Generic Prescription Drugs.
Marksans Pharma Q3 FY24 Financial Performance Highlights
- Marksans Pharma’s Q3 FY24 results show a notable increase in both revenue and profit compared to the previous year, with revenue up by 22.15% YoY and profit rising by 31.27% YoY.
- Quarter-on-quarter (q-o-q), revenue grew by 10.33%, while profit saw a slight decrease of 0.34%.
- Selling, general & administrative expenses rose by 4.78% q-o-q and 19.84% YoY, reflecting increased operational costs.
- Operating income showed significant growth, increasing by 15.17% q-o-q and 73.73% YoY, indicating improved efficiency and profitability.
- Earnings per share (EPS) for Q3 FY24 stood at ₹1.84, marking a 17.95% increase compared to the previous year.
- In terms of returns, Marksans Pharma delivered 3.1% in the last week, 38.61% in the last 6 months, and -1.96% year-to-date (YTD) return.
- The company’s current market capitalization is ₹7157.72 Cr, with a 52-week high/low of ₹179.3 & ₹64.3 respectively, reflecting market sentiment and stock performance over the past year.
Below are the trading platforms that you can use to purchase Marksans Pharma shares:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
| When | Maximum Price | Minimum Price |
| April 2024 | 173.88 | 151.20 |
| May 2024 | 171.31 | 148.97 |
| June 2024 | 177.48 | 154.33 |
| July 2024 | 175.70 | 152.78 |
| August 2024 | 182.73 | 158.90 |
| September 2024 | 190.04 | 165.25 |
| October 2024 | 186.31 | 162.01 |
| November 2024 | 191.90 | 166.87 |
| December 2024 | 196.70 | 171.04 |
In 2024, Marksans Pharma’s share price targets show a positive outlook based on projected maximum and minimum prices for each month. The stock’s value is expected to range between ₹151.20 to ₹196.70 by the end of December 2024, with an increasing trend as the year progresses. The current market capitalization stands at ₹7,296 Cr. As of April 6th, 2024, the share price is ₹161, lower than the year’s high of ₹179 but above the low of ₹70.2. The stock’s Price/Earnings (P/E) ratio is 23.0, reflecting market confidence.
Additionally, key financial metrics include a Book Value of ₹41.4, a Dividend Yield of 0.31%, a Return on Capital Employed (ROCE) of 22.2%, a Return on Equity (ROE) of 18.6%, and a Face Value of ₹1.00. This data provides investors with insights into Marksans Pharma’s financial health and potential growth trajectory.
| When | Maximum Price | Minimum Price |
| January 2025 | 200.63 | 154.33 |
| February 2025 | 205.78 | 158.29 |
| March 2025 | 213.80 | 164.47 |
| April 2025 | 209.61 | 161.24 |
| May 2025 | 203.51 | 156.54 |
| June 2025 | 212.67 | 163.59 |
| July 2025 | 208.50 | 160.38 |
| August 2025 | 214.94 | 165.34 |
| September 2025 | 222.47 | 171.13 |
| October 2025 | 228.25 | 175.58 |
| November 2025 | 233.96 | 179.97 |
| December 2025 | 239.81 | 184.47 |
In 2025, Marksans Pharma’s share price is expected to fluctuate within a range of ₹154.33 to ₹239.81 across the months, indicating potential growth and volatility throughout the year. The projected maximum prices show an upward trend, reaching a peak in December 2025 at ₹239.81. This forecast reflects market expectations and factors influencing Marksans Pharma’s stock performance over the year.
Marksans Pharma boasts a diverse product portfolio with over 1500 Stock Keeping Units (SKUs) and more than 300 products. These include tablets (plain, enteric-coated, and film-coated), hard & soft gelatin capsules, oral liquids, and ointments, catering to a wide range of therapeutic needs and markets.
| When | Maximum Price | Minimum Price |
| January 2026 | 247.00 | 190.00 |
| February 2026 | 253.33 | 194.87 |
| March 2026 | 263.21 | 202.47 |
| April 2026 | 258.05 | 198.50 |
| May 2026 | 250.54 | 192.72 |
| June 2026 | 261.81 | 201.39 |
| July 2026 | 256.68 | 197.44 |
| August 2026 | 264.62 | 203.55 |
| September 2026 | 273.88 | 210.67 |
| October 2026 | 281.00 | 216.15 |
| November 2026 | 288.02 | 221.56 |
| December 2026 | 295.22 | 227.09 |
In 2026, Marksans Pharma’s share price is anticipated to fluctuate between ₹190.00 and ₹295.22 over the year. The maximum price targets, ranging from ₹247.00 to ₹295.22 by December, suggest a potential upward trajectory, reflecting market sentiments and projected growth factors for Marksans Pharma’s stock.
Marksans Pharma has extended its reach beyond traditional markets, expanding into regions like the Middle East, Southeast Asia, CIS, Russia, and Africa. The acquisition of AHC in the UAE signifies a strategic move to bolster its presence in the MENA (Middle East and North Africa) region, tapping into new markets and opportunities for growth.
| When | Maximum Price | Minimum Price |
| January 2027 | 301.13 | 231.64 |
| February 2027 | 308.85 | 237.58 |
| March 2027 | 320.89 | 246.84 |
| April 2027 | 314.60 | 242.00 |
| May 2027 | 305.44 | 234.95 |
| June 2027 | 319.18 | 245.53 |
| July 2027 | 312.92 | 240.71 |
| August 2027 | 322.60 | 248.16 |
| September 2027 | 333.89 | 256.84 |
| October 2027 | 342.58 | 263.52 |
| November 2027 | 351.14 | 270.11 |
| December 2027 | 359.92 | 276.86 |
In 2027, Marksans Pharma’s share price is forecasted to range between ₹231.64 and ₹359.92 throughout the year, indicating potential growth and market fluctuations. The maximum price targets, peaking at ₹359.92 by December, suggest positive sentiment and anticipated performance for Marksans Pharma’s stock.
Marksans Pharma holds several prestigious accreditations from regulatory authorities, including USFDA (U.S. Food and Drug Administration), UK MHRA (Medicines and Healthcare products Regulatory Agency), Australian TGA (Therapeutic Goods Administration), EU (European Union), Health Canada, and the Japanese Health Authority. These accreditations underscore the company’s commitment to quality, compliance, and adherence to stringent regulatory standards across key global markets.
| When | Maximum Price | Minimum Price |
| January 2028 | 367.12 | 282.40 |
| February 2028 | 376.53 | 289.64 |
| March 2028 | 391.21 | 300.93 |
| April 2028 | 383.54 | 295.03 |
| May 2028 | 372.37 | 286.44 |
| June 2028 | 389.13 | 299.33 |
| July 2028 | 381.50 | 293.46 |
| August 2028 | 393.30 | 302.54 |
| September 2028 | 407.06 | 313.13 |
| October 2028 | 417.65 | 321.27 |
| November 2028 | 428.09 | 329.30 |
| December 2028 | 438.79 | 337.53 |
- January 2028: ₹282.40 (Minimum)
- December 2028: ₹438.79 (Maximum)
| When | Maximum Price | Minimum Price |
| January 2029 | 447.57 | 344.28 |
| February 2029 | 459.04 | 353.11 |
| March 2029 | 476.95 | 366.88 |
| April 2029 | 467.59 | 359.69 |
| May 2029 | 453.97 | 349.21 |
| June 2029 | 474.40 | 364.93 |
| July 2029 | 465.10 | 357.77 |
| August 2029 | 479.49 | 368.83 |
| September 2029 | 496.27 | 381.74 |
| October 2029 | 509.17 | 391.67 |
| November 2029 | 521.90 | 401.46 |
| December 2029 | 534.95 | 411.50 |
- January 2029: ₹344.28(Minimum)
- December 2029: ₹534.95 (Maximum)
| When | Maximum Price | Minimum Price |
| January 2030 | 545.65 | 419.73 |
| February 2030 | 559.64 | 430.49 |
| March 2030 | 581.46 | 447.28 |
| April 2030 | 570.06 | 438.51 |
| May 2030 | 553.46 | 425.74 |
| June 2030 | 578.36 | 444.89 |
| July 2030 | 567.02 | 436.17 |
| August 2030 | 584.56 | 449.66 |
| September 2030 | 605.02 | 465.40 |
| October 2030 | 620.75 | 477.50 |
| November 2030 | 636.27 | 489.44 |
| December 2030 | 652.18 | 501.67 |
- January 2030: ₹419.73 (Minimum)
- December 2030: ₹652.18 (Maximum)
Financial Condition of Marksans Pharma: Last 5 Years
| Financials | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Sales (Rs. Crores) | 1,000 | 1,134 | 1,376 | 1,491 | 1,852 |
| Expenses (Rs. Crores) | 868 | 942 | 1,037 | 1,232 | 1,513 |
| Operating Profit (Rs. Crores) | 132 | 192 | 340 | 259 | 340 |
| OPM % | 13% | 17% | 25% | 17% | 18% |
| Other Income (Rs. Crores) | 5 | 0 | 7 | 42 | 59 |
| Interest (Rs. Crores) | 10 | 9 | 8 | 8 | 9 |
| Depreciation (Rs. Crores) | 23 | 27 | 27 | 45 | 52 |
| Profit before tax (Rs. Crores) | 104 | 157 | 302 | 248 | 338 |
| Tax % | 23% | 23% | 21% | 25% | 21% |
| Net Profit (Rs. Crores) | 80 | 121 | 239 | 187 | 265 |
| EPS (Rs.) | 1.87 | 2.95 | 5.83 | 4.51 | 5.88 |
| Dividend Payout % | 3% | 3% | 4% | 6% | 9% |
- Marksans Pharma has shown significant financial growth over the last five years, with sales increasing from ₹1,000 crores in 2019 to ₹1,852 crores in 2023, reflecting a compounded sales growth rate of 18%.
- Despite increasing expenses, the company’s operating profit reached ₹340 crores in 2023, maintaining an operating profit margin (OPM) between 17% and 25% during this period.
- Net profit has notably increased from ₹80 crores in 2019 to ₹265 crores in 2023, resulting in a compounded profit growth rate of 52% over five years.
- The earnings per share (EPS) improved consistently, rising from ₹1.87 in 2019 to ₹5.88 in 2023.
- Marksans Pharma’s stock has performed impressively with compound annual growth rates (CAGR) of 45% over the past five years and 123% in the last year alone.
- The company has maintained a healthy return on equity (ROE) ranging from 19% to 22% over recent years, highlighting its effectiveness in generating returns for shareholders.
FAQs
What is Marksans Pharma’s current market capitalization?
Marksans Pharma’s current market capitalization is ₹7,296 Crores.
The current share price target for Marksans Pharma varies based on monthly predictions, ranging from ₹151.20 to ₹196.70 by December 2024.
Marksans Pharma’s share price targets for 2025 range from ₹154.33 to ₹239.81 by December.
Marksans Pharma’s share price targets for 2030 range from ₹419.73 to ₹652.18 by December.
What is the current Price/Earnings (P/E) ratio of Marksans Pharma?
Marksans Pharma’s current Price/Earnings (P/E) ratio is 23.0.
What is the dividend payout percentage for Marksans Pharma?
Marksans Pharma’s dividend payout percentage is 9%.
How has Marksans Pharma’s sales growth trended over the last 5 years?
Marksans Pharma’s compounded sales growth rate has been 18% over the last 5 years.
How has Marksans Pharma’s profit growth trended over the last 5 years?
Marksans Pharma’s compounded profit growth rate over the last 5 years has been 52%.
What is the current Return on Equity (ROE) for Marksans Pharma?
Marksans Pharma’s current Return on Equity (ROE) is 18.6%.
How has Marksans Pharma’s stock price performed over the last 5 years?
Marksans Pharma’s stock has exhibited a compound annual growth rate (CAGR) of 45% over the last 5 years.
How has Marksans Pharma’s dividend payout percentage evolved over the last 5 years?
Marksans Pharma’s dividend payout percentage has increased from 3% in 2019 to 9% in 2023.
Also Read
- MRF Ltd Share Price Target 2024, 2025, 2026 To 2030
- Softtech Engineers Ltd Share Price Target 2024, 2025, 2026 To 2030
- Poly Medicure Share Price Target 2024, 2025, 2026 To 2030
Concluding Insights: Marksans Pharma’s Path to Success
In conclusion, Marksans Pharma has emerged as a key player in the pharmaceutical sector, showcasing remarkable growth and innovation. With a diverse product portfolio spanning vital therapeutic areas such as Oncology, Gastroenterology, and Cardiovascular medications, the company has demonstrated a strong commitment to advancing healthcare. In FY23, Marksans Pharma’s revenue mix emphasized a strategic focus on Pain Management and Over-the-Counter (OTC) products, which significantly contributed to its overall revenue.
Geographically, Marksans Pharma has established a robust presence in critical markets like the US, Europe, and the UK, supported by the acquisition of Time Cap Labs Inc. in the US. This acquisition has bolstered its market reach, supplying generic and OTC drugs to major retailers.
Financially, Marksans Pharma has delivered impressive results with a compounded sales growth rate of 18% and a remarkable profit growth rate of 52% CAGR over the last five years. The company’s debt-free status underscores its financial stability and operational efficiency.
While there has been a slight decline in promoter holding over the last three years, Marksans Pharma remains well-positioned for sustained growth, driven by its innovative product offerings, expanding market presence, and strong financial performance. With positive projections for share price targets and consistent financial health, Marksans Pharma is poised for continued success in the pharmaceutical industry.
What did we learn?
- 1 About Marksans Pharma
- 2 Marksans Pharma Q3 FY24 Financial Performance Highlights
- 3 How to Purchase Marksans Pharma Shares in India?
- 4 Marksans Pharma Share Price Prediction 2024 – 2030
- 4.1 Marksans Pharma Share Price Target 2024
- 4.2 Marksans Pharma Share Price Target 2025
- 4.3 Marksans Pharma Share Price Target 2026
- 4.4 Marksans Pharma Share Price Target 2027
- 4.5 Marksans Pharma Share Price Target 2028
- 4.6 Marksans Pharma Share Price Target 2029
- 4.7 Marksans Pharma Share Price Target 2030
- 5 Financial Condition of Marksans Pharma: Last 5 Years
- 6 FAQs
- 6.1 What is Marksans Pharma’s current market capitalization?
- 6.2 What is the current share price target for Marksans Pharma?
- 6.3 What is Marksans Pharma’s share price target for 2025?
- 6.4 What is Marksans Pharma’s share price target for 2030?
- 6.5 What is the current Price/Earnings (P/E) ratio of Marksans Pharma?
- 6.6 What is the dividend payout percentage for Marksans Pharma?
- 6.7 How has Marksans Pharma’s sales growth trended over the last 5 years?
- 6.8 How has Marksans Pharma’s profit growth trended over the last 5 years?
- 6.9 What is the current Return on Equity (ROE) for Marksans Pharma?
- 6.10 How has Marksans Pharma’s stock price performed over the last 5 years?
- 6.11 How has Marksans Pharma’s dividend payout percentage evolved over the last 5 years?
- 7 Concluding Insights: Marksans Pharma’s Path to Success
